GLP1R and type 2 diabetes mellitus: Meta‐analysis of eight clinical trials in patients with T2D and MASLD demonstrated a reduction in MRI‐measured hepatic fat when treated with GLP‐1 RAs [26], whilst 24 weeks of semaglutide, specifically, improved liver fat and stiffness as assessed via transient elastography [27].